Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or ...

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing ...
USA Today

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing ...
Amarillo Globe-News

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to ...
MarketWatch

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its ...
The Journal News

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Revelation’s net loss for the three months ended September 30, 2025 was $1.9 million, or $ (1.77) basic and diluted net loss per share compared to a net loss of $2.2 million, or $ (40.15) basic and ...